Warfarin Sodium

Atrial Fibrillation	31.4%
Drug Use For Unknown Indication	13.1%
Deep Vein Thrombosis	11.1%
Thrombosis Prophylaxis	7.5%
Pulmonary Embolism	7.2%
Anticoagulant Therapy	6.1%
Hypertension	2.8%
Product Used For Unknown Indication	2.5%
Thrombosis	2.5%
Cerebrovascular Accident	2.4%
Aortic Valve Replacement	2.1%
Prophylaxis	1.7%
Mitral Valve Replacement	1.5%
Heart Valve Replacement	1.5%
Cerebrovascular Accident Prophylaxis	1.3%
Cardiac Failure	1.2%
Embolism	1.1%
Urinary Tract Infection	1.1%
Coronary Artery Disease	1.1%
Pain	1.1%

International Normalised Ratio Increased	37.5%
Haemorrhage	5.9%
International Normalised Ratio Abnormal	5.8%
Gastrointestinal Haemorrhage	4.5%
International Normalised Ratio Decreased	4.5%
Subdural Haematoma	4.4%
Drug Interaction	4.0%
Rectal Haemorrhage	3.8%
Haemorrhage Intracranial	3.2%
Upper Gastrointestinal Haemorrhage	3.1%
Cerebral Haemorrhage	3.0%
Vomiting	3.0%
Gastric Haemorrhage	3.0%
Melaena	2.8%
Prothrombin Time Prolonged	2.1%
International Normalised Ratio Fluctuation	2.0%
Thrombosis	2.0%
Urinary Tract Infection	1.9%
Haematuria	1.9%
Treatment Noncompliance	1.8%

Secondary

Product Used For Unknown Indication	20.1%
Drug Use For Unknown Indication	18.1%
Atrial Fibrillation	11.0%
Thrombosis Prophylaxis	7.2%
Hypertension	5.3%
Deep Vein Thrombosis	4.8%
Anticoagulant Therapy	4.6%
Cardiac Failure	3.9%
Prophylaxis	3.7%
Embolism	3.5%
Pulmonary Embolism	3.5%
Cardiac Failure Chronic	2.4%
Depression	2.1%
Pain	1.9%
Urinary Tract Infection	1.7%
Thrombosis	1.3%
Diabetes Mellitus	1.3%
Malignant Lymphoid Neoplasm	1.3%
Insomnia	1.2%
Anxiety	1.2%

International Normalised Ratio Increased	29.7%
Drug Interaction	5.9%
Gastrointestinal Haemorrhage	5.6%
Hallucination	5.4%
International Normalised Ratio Decreased	4.8%
Vomiting	4.1%
Haemorrhage	4.0%
Cerebral Haemorrhage	3.8%
Prothrombin Time Prolonged	3.7%
Completed Suicide	3.5%
Death	3.3%
Renal Failure Acute	3.3%
Weight Decreased	3.3%
Pulmonary Embolism	3.2%
Epistaxis	3.0%
Thrombosis	3.0%
Rectal Haemorrhage	2.9%
Renal Failure	2.5%
White Blood Cell Count Increased	2.5%
Haematuria	2.5%

Concomitant

Product Used For Unknown Indication	30.6%
Drug Use For Unknown Indication	26.0%
Hypertension	7.1%
Atrial Fibrillation	6.3%
Multiple Myeloma	3.4%
Prophylaxis	2.8%
Pain	2.8%
Rheumatoid Arthritis	2.8%
Diabetes Mellitus	2.2%
Pulmonary Arterial Hypertension	1.9%
Cardiac Failure	1.7%
Depression	1.6%
Pulmonary Hypertension	1.6%
Anticoagulant Therapy	1.6%
Cardiac Disorder	1.5%
Blood Cholesterol Increased	1.5%
Osteoporosis	1.4%
Thrombosis Prophylaxis	1.2%
Constipation	1.0%
Chronic Obstructive Pulmonary Disease	1.0%

Vomiting	13.2%
Weight Decreased	9.3%
Death	8.0%
Pneumonia	5.5%
Pulmonary Embolism	5.4%
International Normalised Ratio Increased	5.2%
Weight Increased	4.8%
Dyspnoea	4.5%
Nausea	4.3%
Drug Ineffective	4.3%
Cardiac Failure	4.3%
Renal Failure Acute	4.1%
Pain	3.8%
Thrombosis	3.6%
Pyrexia	3.4%
Urinary Tract Infection	3.4%
Vision Blurred	3.3%
Atrial Fibrillation	3.3%
Rash	3.2%
Oedema Peripheral	3.2%

Interacting

Drug Use For Unknown Indication	24.7%
Product Used For Unknown Indication	17.3%
Atrial Fibrillation	15.1%
Hypertension	5.0%
Oral Candidiasis	4.4%
Anticoagulant Therapy	3.7%
Deep Vein Thrombosis	3.3%
Pulmonary Embolism	3.1%
Pneumonia	3.0%
Prophylaxis	2.6%
Pain	2.4%
Cardiac Failure	2.1%
Complex Partial Seizures	2.0%
Cerebral Infarction	1.8%
Periorbital Cellulitis	1.8%
Angina Pectoris	1.7%
Depression	1.7%
Hyperlipidaemia	1.5%
Urinary Tract Infection	1.5%
Asthma	1.4%

International Normalised Ratio Increased	38.5%
Drug Interaction	25.2%
International Normalised Ratio Decreased	7.0%
Prothrombin Time Prolonged	3.2%
Malaise	2.7%
Pneumonia	2.5%
Retroperitoneal Haematoma	2.2%
Epistaxis	2.0%
Haemorrhage	1.7%
Melaena	1.7%
Syncope	1.7%
Weight Decreased	1.7%
Haematuria	1.5%
Thrombosis	1.5%
Purpura	1.3%
Pyrexia	1.3%
Haemorrhage Subcutaneous	1.2%
Retinal Haemorrhage	1.2%
White Blood Cell Count Increased	1.2%
Atrial Fibrillation	1.0%